Type 1 diabetes

Semaglutide in Adults with Type 1 Diabetes and Obesity

NEJM EvidPublished Randomised controlled trial

Primary result · Primary composite outcomeResult — go to the resultBetween-group difference 36 percentage points 95% CI 20.6–52.2

Authors' conclusion

In adults with type 1 diabetes and obesity, semaglutide treatment, compared with AID use alone, significantly improved achievement of a composite of time in range of greater than 70%, with time below range of less than 4%, and a 5% body weight reduction.

Study context

Population
Adults with T1D using an automated insulin delivery (AID) system and BMI ≥30randomized 1:1
Participants
72 adults
Comparison
Once-weekly semaglutide vs placebo
Primary endpoint
Composite:
  • Continuous glucose monitoring (CGM) time 70–180 mg/dl >70%
  • Time <70 mg/dl <4%
  • Weight reduction ≥5%
Follow-up
26 weeks
Methodological detailsdouble-blind, placebo-controlled
  • Double-blind
  • Placebo-controlled

Primary result

Primary composite outcome

Between-group difference

36 percentage points

95% CI 20.6–52.2

P < 0.001

By group

Semaglutidevs Placebo
between-group difference 36 percentage points (95% CI 20.6–52.2); P < 0.001

As reported in the abstract

Further findings

OutcomeDifference in least-squares mean change (percentage points) (95% CI)
HbA1c, least-squares mean change from baseline · week 26−0.3 (−0.6 to −0.05)
CGM time 70–180 mg/dl, least-squares mean change from baseline · week 268.8 (3.9–13.7)
OutcomeDifference in least-squares mean change (kg) (95% CI)
Body weight, least-squares mean change from baseline · week 26−8.8 (−10.6 to −7.0)

Safety

Events

OutcomeSemaglutidePlacebo
Severe hypoglycemia events22

DKA

No DKA reported

Original publication

Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. Published 23 June 2025. doi:10.1056/evidoa2500173

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.